Endogenous hypercortisolism (eHC), though classically associated with features such as central adiposity and moon facies, often manifests in far more subtle and protean ways, leading to delayed recognition and suboptimal treatment outcomes. Advances in understanding the pathophysiology of cortisol dysregulation have reshaped clinical approaches, paving the way for selective cortisol modulators and other novel therapeutics that target the underlying mechanisms of disease.
This multidisciplinary grand rounds program brings together experts in endocrinology, cardiology, and internal medicine to examine the evolving landscape of diagnosis and management in endogenous hypercortisolism. Through interactive case discussions and reviews of current and emerging evidence—including a review of the design of the ongoing MOMENTUM study (NCT06829537) that assesses the prevalence of eHC among patients with resistant hypertension—participants will gain deeper insight into the systemic consequences of cortisol excess and strategies for optimizing care.
Cardiologists, endocrinologists, nephrologists, other internists, and other healthcare providers who contribute to the potential identification and management of patients with endogenous hypercortisolemia
Investigate the mechanism of action for emerging therapeutics for endogenous hypercortisolism including selective cortisol modulators in order to be prepared for their availability
Explore the protean manifestations of endogenous hypercortisolism in order to accurately diagnose and treat these conditions to improve cardiovascular and endocrine outcomes
Evaluate the standard diagnostic approach and latest evidence for emerging therapeutics for endogenous hypercortisolism in order to update treatment plans when these therapeutics are available
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty
have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Deepak L. Bhatt, MD, MPH, MBA (Course Chair) | Advisory Board: Angiowave; Antlia Bioscience; Bayer AG; Boehringer Ingelheim International GmbH; CellProthera; Cereno Scientific; E-Star Biotech; High Enroll; Janssen Pharmaceuticals, Inc, Level Ex; McKinsey; Medscape Cardiology; Merck & Co., Inc.; NirvaMed; Novo Nordisk A/S; Repair Biotechnologies; Stasys; Tourmaline Bio Board of Directors: American Heart Association New York City; Angiowave (Stock Options); Bristol Myers Squibb (Stock); DRS.LINQ (Stock Options); High Enroll (Stock) Consultant: Alnylam; Altimmune; Broadview Ventures; Corcept Therapeutics; Corsera; GlaxoSmithKline; Hims; SERB; SFJ; Summa Therapeutics; Worldwide Clinical Trials Data Monitoring Committees: Acesion Pharma; Assistance Publique-Hôpitaux de Paris; Baim Institute for Clinical Research; Boston Scientific (Chair, PEITHO Trial), Cleveland Clinic; Contego Medical (Chair, PERFORMANCE 2); Duke Clinical Research Institute; Mayo Clinic; Mount Sinai School of Medicine (for the ABILITY-DM Trial, funded by Concept Medical; for ALLAY-HF, funded by Alleviant Medical); Novartis; Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial) Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee); Arnold and Porter Law Firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation); Baim Institute for Clinical Research (AEGIS-II executive committee funded by CSL Behring); Belvoir Publications (Editor in Chief, Harvard Heart Letter); Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees); CSL Behring (AHA lecture); Duke Clinical Research Institute; Engage Health Media; HMP Global (Editor in Chief, Journal of Invasive Cardiology); Medtelligence/ReachMD (CME steering committees); MJH Life Sciences; Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology); Philips (Becker's Webinar on AI); Population Health Research Institute; WebMD (CME steering committees); Wiley (steering committee) Other: Clinical Cardiology (Deputy Editor); Progress in Cardiovascular Diseases (Deputy Editor) Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent) Research Funding: Abbott; Acesion Pharma; Afimmune; Alnylam; Amarin; Amgen; AstraZeneca; Atricure; Bayer AG; Boehringer Ingelheim International GmbH; Boston Scientific; CellProthera; Cereno Scientific; Chiesi; Cleerly; CSL Behring; Faraday Pharmaceuticals; Fractyl; Idorsia; Janssen Pharmaceuticals, Inc; Javelin; Lexicon; Lilly; Medtronic; Merck & Co., Inc.; MiRU; Moderna; Novartis AG; Novo Nordisk A/S; Pfizer; PhaseBio; Regeneron; Reid Hoffman Foundation; Roche; Sanofi; Stasys; 89Bio Royalties: Elsevier (Editor, Braunwald’s Heart Disease) Site Co-Investigator: Cleerly |
| Omar Al Dhaybi, MD, MSc, FASN | Consultant/Advisor: AstraZeneca; Medtronic, Inc. |
| Vanita R. Aroda, MD | Consultant/Advisor: Applied Therapeutics; Biomea Fusion, Inc.; Fractyl Health, Inc.; Novo Nordisk A/S; Pfizer Inc; Recordati; Sanofi; Servier Pharmaceuticals; Roche Grant/Research Support: Applied Therapeutics; Boehringer Ingelheim International GmbH; Corcept Therapeutics, Incorporated; Fractyl Health, Inc.; Lilly; Novo Nordisk A/S; Pfizer Inc; Rhythm Pharmaceuticals, Inc. |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Joseph Feick, PharmD; Nicole McMenamin and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM.
AcademicCME designates this enduring material for a maximum of 0.25 CNE Contact Hours, including 0.25 Pharmacotherapeutic Contact Hours (Provider #P0491).
AcademicCME designates this continuing education activity for 0.25 CPE Contact Hours (0.025 CEUs) of Continuing Pharmacy Education Credit (UAN #JA4008190-0000-25-033-H01-P).
This activity has been supported by an independent educational grant from Corcept Therapeutics, Incorporated.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Corcept Therapeutics, Incorporated do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606
